David Demski Sells 30,000 Shares of Alphatec (NASDAQ:ATEC) Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) Director David Demski sold 30,000 shares of the business’s stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $21.20, for a total value of $636,000.00. Following the transaction, the director directly owned 399,623 shares of the company’s stock, valued at $8,472,007.60. The trade was a 6.98% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Alphatec Trading Up 0.3%

Shares of Alphatec stock opened at $19.96 on Friday. The company has a debt-to-equity ratio of 43.02, a current ratio of 1.99 and a quick ratio of 1.24. Alphatec Holdings, Inc. has a 1 year low of $8.69 and a 1 year high of $22.66. The firm has a market cap of $2.97 billion, a PE ratio of -19.19 and a beta of 1.08. The company has a 50 day simple moving average of $18.42 and a two-hundred day simple moving average of $15.10.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings data on Thursday, October 30th. The medical technology company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.09. The company had revenue of $196.50 million for the quarter, compared to the consensus estimate of $182.78 million. During the same period in the prior year, the firm posted ($0.28) earnings per share. The business’s revenue was up 30.4% on a year-over-year basis. Analysts expect that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alphatec in a research note on Monday, December 8th. Lake Street Capital set a $25.00 price objective on shares of Alphatec and gave the company a “buy” rating in a research note on Friday, October 31st. Needham & Company LLC lifted their target price on shares of Alphatec from $16.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Loop Capital set a $25.00 price target on shares of Alphatec in a research note on Wednesday. Finally, Barclays raised their price objective on Alphatec from $22.00 to $23.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Alphatec presently has an average rating of “Moderate Buy” and a consensus price target of $22.45.

Institutional Trading of Alphatec

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Creative Planning raised its stake in Alphatec by 0.9% during the third quarter. Creative Planning now owns 58,654 shares of the medical technology company’s stock valued at $853,000 after buying an additional 534 shares during the last quarter. Valeo Financial Advisors LLC raised its position in shares of Alphatec by 2.1% in the 3rd quarter. Valeo Financial Advisors LLC now owns 41,296 shares of the medical technology company’s stock worth $600,000 after purchasing an additional 846 shares during the last quarter. Norden Group LLC grew its position in Alphatec by 2.6% during the 3rd quarter. Norden Group LLC now owns 36,676 shares of the medical technology company’s stock valued at $533,000 after purchasing an additional 939 shares during the last quarter. Arizona State Retirement System increased its stake in Alphatec by 2.8% during the 3rd quarter. Arizona State Retirement System now owns 34,603 shares of the medical technology company’s stock valued at $503,000 after purchasing an additional 949 shares in the last quarter. Finally, Ameritas Investment Partners Inc. raised its holdings in Alphatec by 8.8% in the second quarter. Ameritas Investment Partners Inc. now owns 11,845 shares of the medical technology company’s stock worth $131,000 after buying an additional 955 shares during the last quarter. Hedge funds and other institutional investors own 66.35% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.